Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Observational Study of the Effectiveness of Elranatamab in Patients With Relapsed and/or Refractory Multiple Myeloma in Taiwan

NCT07391761 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07391761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07391761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Observational Study of the Effectiveness of Elranatamab in Patients With Relapsed and/or Refractory Multiple Myeloma in Taiwan
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
May 11, 2026
Completion date
January 31, 2028
Enrollment
1 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma (rrmm)